Medical Learning Institute, Inc.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.